Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer

Breast

Volumn 19, Issue 2, 2010, Pages 128-132

  Iorfida, Monica ^a   Bagnardi, Vincenzo ^a,c,d   Balduzzi, Alessandra ^a   Dellapasqua, Silvia ^a   Cardillo, Anna ^a   Luini, Alberto ^a   Intra, Mattia ^a   Minchella, Ida ^a   Veronesi, Paolo ^a   Viale, Giuseppe ^a,b   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Frontier Science and Technology Research Foundation   (Italy)

Author keywords

Breast cancer; Oral vinorelbine; Preoperative therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; LETROZOLE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; TRIPTORELIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOT FLUSH; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LOADING DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH PAIN; VOMITING;

EID: 77951204959     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.12.011     Document Type: Article

References (33)

1. Lazaridis G., Pentheroudakis G., Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008, 66:31-41.
2. ®) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007, 18:1152-1158.
3. Burstein H.J., Keshaviah A., Baron A.D., Hart R.D., Lambert-Falls R., Marcom P.K., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane Study. Cancer 2007, 110(5):965-972.
4. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13:1198-1207.
5. Bartsch R., Wenzel C., Altorjai G., Pluschnig U., Bachleitner-Hoffmann T., Locker G.J., et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007, 102:375-381.
6. Catania C., Medici M., Magni E., Munzone E., Cardinale D., Adamoli L., et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 2007, 18:1969-1975.
7. Torrisi R., Bagnardi V., Pruneri G., Ghisini R., Bottiglieri L., Magni E., et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007, 97(6):802-808.
8. Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10:6622-6628.
9. Colleoni M., Minchella I., Mazzarol G., Nole F., Peruzzotti G., Rocca A., et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesteron receptors. Ann Oncol 2000, 11:1057-1059.
10. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
11. Kuerer H.M., Newman L.A., Smith T.M., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
12. Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037-1044.
13. Kaufmann M., von Minckwitz G., Smith R., Valero V., Gianni L., Eiermann W., et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003, 21:2600-2608.
14. Colleoni M., Viale G., Zahrieh D., Bottiglieri L., Gelber R.D., Veronesi P., et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 2008, 19:465-472.
15. Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., McGale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1934.
16. von Minckwitz G., Costa S.D., Raab G., Blohmer J.U., Eidtmann H., Hilfrich J., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001, 19:3506-3515.
17. Albain K.S. Adjiuvant chemo-endocrine therapy for breast cancer: combined or sequential?. The Breast 2003, 12:12.
18. Fersis N., Smyczek-Gargya B., Armeanu S., Gagulic E., Pantic L., Relakis K., et al. Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. Eur J Gynecol Oncol 2004, 25:45-50.
19. Torrisi R., Dellapasqua S., Ghisini R., Viale G., Veronesi P., Luini A., et al. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. The Breast 2008, 17:654-660.
20. Torrisi R., Bagnardi V., Cardillo A., Bertolini F., Scarano E., Orlando L., et al. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008, 99:1564-1571.
21. D'Alessandro C., Dellapasqua S., Orlando L., Santoro L., Maisonneuve P., Torrisi R., et al. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Breast J 2008, 14:435-441.
22. Andre F., Chafika M., Cornelia L., Kau S.W., Frye D., Green M., et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2008, 108:183-190.
23. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23(16):3676-3685.
24. Gianni L., Eiermann W., Semiglazov V., Manikhas G., Lluch A., Tjulandin S., et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Cancer Res 2009, 69(Suppl. 2). Abstr 31.
25. Peitinger F., Buzdar A.U., Kuerer H.M., Mejia J.A., Hatzis C., Gonzalez-Angulo A.M., et al. Hormone receptor and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008, 19:2020-2025.
26. Shou J., Massarwesh S., Osbourne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2 cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
27. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20:1467-1472.
28. Read L.D., Keith D., Slamon D.J., Katzenellenbogen B.S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p1875 protein expression in human breast cancer cell lines. Cancer Res 1990, 50:3947-3951.
29. Marcom P.K., Isaacs C., Harris L., Wong Z.W., Kommarreddy A., Novielli N., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007, 102:43-49.
30. Mackey J.R., Kaufman B., Clemens M., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab prolongs progression free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl. 1):S5. (Abstr 3).
31. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100(19):1380-1388.
32. Locker A.P., Birrelli K., Bell J.A., Nicholson R.I., Elston C.W., Blamey R.W., et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 1992, 18:224-229.
33. Urriticoechea A., Smith I.E., Dowsett M. Proliferative marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220.